Monitor Toxicity, Anti-Cancer Drug Efficacy and Cytokine Response with New Bioluminescent Cytotoxicity Technology
Complete the form below to unlock access to ALL audio articles.
Promega Corporation has announced the launch of the CytoTox-Glo™ Cytotoxicity Assay at the 5th annual Screening Europe conference and exhibition. Whether monitoring chemical toxicity, anti-cancer drug efficacy or cytokine response, the CytoTox-Glo Assay is designed to provide a sensitive, simple, luminescent method that allows the user to detect small changes in cell viability.
The assay measures a distinct “dead-cell” protease biomarker released from cells that have lost membrane integrity, a key indicator of cytotoxicity. The assay uses a peptide substrate, that after cleavage by the “dead-cell” protease, releases luciferin. This is a substrate for a proprietary thermostable luciferase (Ultra-Glo™ Recombinant Luciferase).
The luciferase/luciferin reaction produces light in the form of a stable “glow-type” luminescent signal. The intensity of the signal correlates with dead-cell number.
The CytoTox-Glo Assay has a large dynamic range with linearity, providing unprecedented sensitivity in 96-well plates or high-density formats. The high sensitivity and scalability minimizes both the number of cells required and the amount of compound used. Features of this assay are detailed in a talk by Promega.
